News | June 26, 2019

Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder EVANSTON, Ill., June 26, 2019 (GLOBE NEWSWIRE) — Aptinyx Inc. (Nasdaq: APTX), a...

News | June 10, 2019

Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain NYX-2925 demonstrated statistically significant effects on a range of neuroimaging...